To (1) evaluate this MAHVI quality improvement initiative, (2) compare MAHVI depression Napabucasin chemical structure recognition rates with those of other hospitals, and (3) examine health care providers’ implementation feedback, we compared the results of

the MAHVI screening program with data from a parallel prospective acute myocardial infarction registry and interviewed MAHVI providers. Depressive symptoms (PHQ-2, PHQ-9) were assessed among 503 MAHVI acute myocardial infarction patients and compared with concurrent depression assessments among 3533 patients at 23 US centers without a screening protocol. A qualitative summary of providers’ suggestions for improvement was also generated. A total of 135 (26.8%) eligible MAHVI patients did not get screened. Among screened patients, 90.9% depressed (PHQ-9 >= 10) patients were recognized. The agreement between the screening and registry data using the full PHQ-9 was 61.5% for positive cases (PHQ-9 >= 10) but only 35.6% for the PHQ-2 alone. Although MAHVI had a slightly higher overall depression recognition rate (38.3%) than other centers not using a depression screening protocol (31.5%), buy BIX 01294 the difference was not statistically significant (P=0.31). Staff feedback suggested that a single-stage

screening protocol with continuous feedback could improve compliance.\n\nConclusions-In this early effort to implement a depression screening protocol, a large proportion of patients did not get screened, and only a modest impact on depression recognition rates was realized. Simplifying the protocol by using the PHQ-9 alone and providing more support and feedback may improve the rates of depression detection and treatment. Pim inhibitor (Circ Cardiovasc Qual Outcomes. 2011; 4: 283-292.)”
“The objective is to estimate the national economic costs

associated with undiagnosed diabetes mellitus (UDM). UDM is defined as unknowingly having an elevated glucose level that meets the definition of diabetes. National Health and Nutrition Examination Survey (NHANES) data are used to estimate the prevalence of UDM. Because UDM cannot be directly observed in medical claims for analyzing per capita patterns of health care use, we analyze annual medical claims from a proxy population-people within 2 years of first diagnosis of diabetes. For a commercially insured population first diagnosed with diabetes in 2006 (n = 29,770), we compare their annual health care use in 2004 and 2005 to that of patients with no history of diabetes between 2004 and 2006 (n = 3.2 million). We combine estimates of UDM prevalence from NHANES with health care use patterns from the proxy population to estimate etiological fractions that reflect the portion of national health care use associated with UDM. Approximately 6.3 million adults in the United States have UDM in 2007.